ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

AKTX Akari Therapeutics PLC

1.42
-0.05 (-3.40%)
04 May 2024 - Closed
Delayed by 15 minutes
Name Symbol Market Type
Akari Therapeutics PLC NASDAQ:AKTX NASDAQ Depository Receipt
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  -0.05 -3.40% 1.42 1.15 1.75 1.59 1.33 1.45 20,772 01:00:00

Report of Foreign Issuer (6-k)

15/05/2017 10:39pm

Edgar (US Regulatory)


 

UNITED STATES

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

May 2017

 

Commission file number: 001-36288

 

Akari Therapeutics, Plc

(Translation of registrant's name into English)

 

75/76 Wimpole Street

London W1G 9RT

United Kingdom

Tel: (646) 448-8743

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F   x        Form 40-F  ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____

 

 

 

 

CONTENTS

 

For the three-month period ended March 31, 2017, Akari Therapeutics, Plc prepared its quarterly report under United States generally accepted accounting principles (“U.S. GAAP”). This quarterly report is furnished herewith as Exhibit 99.1 and incorporated by reference herein.

 

The information contained in this report (including the exhibit hereto) is hereby incorporated by reference into the Company’s Registration Statement on Form S-3, File No. 333-207443, Form S-8 (No. 333-198109 and 333-207444), Registration Statement on Form F-3 File No. 333-198107, and the Registration Statements on Post-Effective Amendments to Form F-1 on Form F-3 (333-185247, 333-187826 and 333-191880).

 

 

Exhibit No.

 

99.1 U.S. GAAP Quarterly Report for the Period Ended March 31, 2017

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Akari Therapeutics, Plc  
  (Registrant)  
       
  By: /s/ Robert M. Shaw  
  Name:   Robert M. Shaw  
  General Counsel & Secretary  

       

Date: May 15, 2017

 

 

1 Year Akari Therapeutics Chart

1 Year Akari Therapeutics Chart

1 Month Akari Therapeutics Chart

1 Month Akari Therapeutics Chart

Your Recent History

Delayed Upgrade Clock